Topical Sustained Delivery of Miltefosine Via Drug-Eluting Contact Lenses to Treat Acanthamoeba Keratitis.
PLGA
acanthamoeba keratitis
contact lens
controlled drug delivery
miltefosine
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
08 Dec 2022
08 Dec 2022
Historique:
received:
12
10
2022
revised:
18
11
2022
accepted:
23
11
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
24
12
2022
Statut:
epublish
Résumé
This study aimed to develop a miltefosine-eluting contact lens (MLF-CL) device that would allow sustained and localized miltefosine release for the treatment of Acanthamoeba keratitis. MLF-CLs were produced in three different miltefosine doses by solvent-casting a thin miltefosine-polymer film around the periphery of a methafilcon hydrogel, which was then lathed into a contact lens. During seven days of in vitro testing, all three formulations demonstrated sustained release from the lens at theoretically therapeutic levels. Based on the physicochemical characterization of MLF-CLs, MLF-CL's physical properties are not significantly different from commercial contact lenses in terms of light transmittance, water content and wettability. MLF-CLs possessed a slight reduction in compression modulus that was attributed to the inclusion of polymer-drug films but still remain within the optimal range of soft contact lenses. In cytotoxicity studies, MLF-CL indicated up to 91% viability, which decreased proportionally as miltefosine loading increased. A three-day biocompatibility test on New Zealand White rabbits revealed no impact of MLF-CLs on the corneal tissue. The MLF-CLs provided sustained in vitro release of miltefosine for a week while maintaining comparable physical features to a commercial contact lens. MLF-CL has a promising potential to be used as a successful treatment method for Acanthamoeba keratitis.
Identifiants
pubmed: 36559244
pii: pharmaceutics14122750
doi: 10.3390/pharmaceutics14122750
pmc: PMC9781349
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cochrane Database Syst Rev. 2015 Feb 24;(2):CD010792
pubmed: 25710134
Biomaterials. 2019 Oct;217:119285
pubmed: 31299627
ISRN Dent. 2014 Mar 03;2014:191068
pubmed: 24724032
Indian J Ophthalmol. 2017 Nov;65(11):1079-1086
pubmed: 29133630
Ophthalmic Physiol Opt. 2006 Jan;26(1):57-64
pubmed: 16390483
Pathogens. 2021 Mar 10;10(3):
pubmed: 33801905
J Eukaryot Microbiol. 2006 Mar-Apr;53(2):121-6
pubmed: 16579814
Parasitol Res. 2012 Feb;110(2):515-20
pubmed: 21748351
Optom Vis Sci. 2006 Dec;83(12):874-8
pubmed: 17164679
Eye Contact Lens. 2013 Jan;39(1):100-8
pubmed: 23274760
Toxicol In Vitro. 2011 Jun;25(4):944-50
pubmed: 21396440
Clin Exp Ophthalmol. 2018 Aug;46(6):600-607
pubmed: 29412494
Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2813-20
pubmed: 11687522
Colloids Surf B Biointerfaces. 2010 Jan 1;75(1):1-18
pubmed: 19782542
Am J Ophthalmol. 2021 Mar;223:75-82
pubmed: 33045218
Ophthalmology. 2016 Oct;123(10):2085-92
pubmed: 27586444
Clin Ophthalmol. 2018 Dec 10;12:2567-2573
pubmed: 30573947
Langmuir. 2007 Jun 19;23(13):6875-8
pubmed: 17503858
Antimicrob Agents Chemother. 2002 Mar;46(3):695-701
pubmed: 11850250
Clin Exp Ophthalmol. 2014 Mar;42(2):151-8
pubmed: 23601234
Eye (Lond). 2008 Oct;22(10):1223-32
pubmed: 18327158
Ocul Surf. 2017 Oct;15(4):670-679
pubmed: 28602948
Ocul Surf. 2007 Oct;5(4):294-307
pubmed: 17938839
Int J Antimicrob Agents. 2022 Jan;59(1):106459
pubmed: 34695563
Sci Rep. 2019 Sep 6;9(1):12821
pubmed: 31492880
Int J Nanomedicine. 2019 Jul 12;14:5187-5199
pubmed: 31371955
J Antimicrob Chemother. 2009 Sep;64(3):539-45
pubmed: 19549672
J Pharm Pharmacol. 2016 Jul;68(7):862-72
pubmed: 27230300
Parasite. 2015;22:10
pubmed: 25687209
Mol Ther. 2017 Jul 5;25(7):1718-1729
pubmed: 28624262
Cont Lens Anterior Eye. 2017 Apr;40(2):70-81
pubmed: 27884616
Cornea. 2019 Jul;38(7):914-917
pubmed: 31170106
Polymers (Basel). 2011 Sep 1;3(3):1377-1397
pubmed: 22577513
Eur J Pharm Biopharm. 2018 Jul;128:220-229
pubmed: 29730260
Ocul Surf. 2022 Jul;25:26-36
pubmed: 35462076
Ocul Immunol Inflamm. 2021 Nov 17;29(7-8):1576-1584
pubmed: 32469616
Acta Biomater. 2020 Oct 15;116:149-161
pubmed: 32814140
Invest Ophthalmol Vis Sci. 2011 Aug 09;52(9):6286-91
pubmed: 21527380
Antimicrob Agents Chemother. 2019 Dec 20;64(1):
pubmed: 31685474
Antimicrob Agents Chemother. 2019 Jun 24;63(7):
pubmed: 31036692
Int Ophthalmol Clin. 2008 Spring;48(2):43-51
pubmed: 18427260
Ocul Immunol Inflamm. 2021 Feb 17;29(2):278-281
pubmed: 31829774
CLAO J. 1994 Jan;20(1):45-8
pubmed: 8149574
Int J Nanomedicine. 2021 May 11;16:3255-3273
pubmed: 34012260
J Appl Polym Sci. 2019 Feb 5;136(5):
pubmed: 31534270
Ophthalmology. 2019 May;126(5):768-770
pubmed: 30572075
Ophthalmic Physiol Opt. 2021 Jan;41(1):116-135
pubmed: 33119189
Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3346-52
pubmed: 19136709
Ocul Surf. 2010 Apr;8(2):70-9
pubmed: 20427010
Cornea. 2016 May;35(5):713-20
pubmed: 26989955
PLoS One. 2019 Sep 6;14(9):e0222092
pubmed: 31491000
J Biomech Eng. 2007 Apr;129(2):156-63
pubmed: 17408320
Eur J Pharm Sci. 2018 Jun 5;121:281-286
pubmed: 29883726
AAPS PharmSciTech. 2021 Mar 14;22(3):107
pubmed: 33719019
J Control Release. 2022 May;345:625-645
pubmed: 35321827
Lancet Microbe. 2021 Aug;2(8):e345-e346
pubmed: 35544193
Eye Contact Lens. 2019 Jan;45(1):23-27
pubmed: 29944508
Ocul Immunol Inflamm. 2022 May 19;30(4):1027-1028
pubmed: 33560165
Biomaterials. 2014 Jan;35(1):432-9
pubmed: 24094935
Exp Eye Res. 2021 Jan;202:108365
pubmed: 33221372
Am J Ophthalmol Case Rep. 2019 Sep 19;16:100555
pubmed: 31650083
Ophthalmic Physiol Opt. 2016 Mar;36(2):77-92
pubmed: 26691018